Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma

References

• C. Statistical Report: Primary Brain Tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States. 2005; 34
   Google Scholar
• Abrey L E, Yahalom J, DeAngelis L M. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144–3150
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O'Neill A, Grossman S A, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21: 1044–1049
   PubMed Web of Science ®Google Scholar
• DeAngelis L M, Seiferheld W, Schold S C, Fisher B, Schultz C J. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy oncology group study 93-10. J Clin Oncol 2002; 20: 4643–4648
   PubMed Web of Science ®Google Scholar
• Panageas K S, Elkin E B, DeAngelis L M, Ben-Porat L, Abrey L E. Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis. Cancer 2005; 104: 2466–2472
   PubMed Web of Science ®Google Scholar
• Panageas K S, Elkin E B, Ben-Porat L, Deangelis L M, Abrey L E. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007
   PubMed Web of Science ®Google Scholar
• Diamond C, Taylor T H, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106: 128–135
   PubMed Web of Science ®Google Scholar
• Kadan-Lottick N S, Skluzacek M C, Gurney J G. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002; 95: 193–202
   PubMed Web of Science ®Google Scholar
• Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 2(Suppl 8)115–121
   Web of Science ®Google Scholar
• Wolf T, Brodt H R, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm E B, et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2005; 46: 207–215
   PubMed Web of Science ®Google Scholar
• Robotin M C, Law M G, Milliken S, Goldstein D, Garsia R J, Dolan G M, et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med 2004; 5: 377–384
   PubMed Web of Science ®Google Scholar
• Fasciano N J, Cherlow A L, Turner B J, Thornton C V. Profile of Medicare beneficiaries with AIDS: application of an AIDS casefinding algorithm. Health Care Financ Rev 1998; 19: 19–38
   PubMed Web of Science ®Google Scholar
• Cleves M A, Sanchez N, Draheim M. Evaluation of two competing methods for calculating Charlson's comorbidity index when analyzing short-term mortality using administrative data. J Clin Epidemiol 1997; 50: 903–908
   PubMed Web of Science ®Google Scholar
• Sambamoorthi U, Collins S, Crystal S. Dually eligible individuals with AIDS: characteristics and health services use. J Health Soc Policy 2001; 14: 19–35
   PubMedGoogle Scholar
• Bozzette S A, Berry S H, Duan N, Frankel M R, Leibowitz A A, Lefkowitz D, Emmons C A, et al. The care of HIV-infected adults in the United States. HIV cost and services utilization study consortium. N Engl J Med 1998; 339: 1897–1904
   PubMed Web of Science ®Google Scholar
• Bower M, Fife K, Sullivan A, Kirk S, Phillips R H, Nelson M, et al. Treatment outcome in presumed and confirmed AIDS-related primary cerebral lymphoma. Eur J Cancer 1999; 35: 601–604
   PubMed Web of Science ®Google Scholar
• Ling S M, Roach M I II, Larson D A, Wara W M. Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer 1994; 73: 2570–2582
   PubMed Web of Science ®Google Scholar
• McAllister L D, Doolittle N D, Guastadisegni P E, Kraemer D F, Lacy C A, Crossen J R, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46: 51–60, discussion 60–61
   PubMed Web of Science ®Google Scholar
• Jacomet C, Girard P M, Lebrette M G, Farese V L, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997; 11: 1725–1730
   PubMed Web of Science ®Google Scholar
• Chamberlain M C, Kormanik P A. AIDS-related central nervous system lymphomas. J Neurooncol 1999; 43: 269–276
   PubMed Web of Science ®Google Scholar
• Aboulafia D M, Ratner L, Miles S A, Harrington W J, Jr. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS malignancies consortium pilot study 019. Clin Lymphoma Myeloma 2006; 6: 399–402
   PubMedGoogle Scholar
• Cunningham W E, Markson L E, Andersen R M, Crystal S H, Fleishman J A, Golin C, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS consortium. HIV cost and services utilization. J Acquir Immune Defic Syndr 2000; 25: 115–123
   PubMed Web of Science ®Google Scholar
• Ghani A C, Donnelly C A, Anderson R M. Patterns of antiretroviral use in the United States of America: analysis of three observational databases. HIV Med 2003; 4: 24–32
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology. Central nervous system cancers V.1.2008. [Internet]; 2008 2/27/2008, Available from: http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf
   Google Scholar